Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novo Nordisk A/S (NOVO-B.CO)
Bagsvaerd, DK
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +2.61% | +25.58% | -1.42% | -5.87% | -8.49% | -31.54% | -48.59% | +26.22% | +70.40% | +34,703.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 18 | 0 |
| Sell | 1 | +1 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+6.4% Q1'26: +24.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+1.8% Q1'26: +67.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+33.5% Q1'26: +12.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+43.6% ★ Q1'26: +67.8% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+35.5% ★ Q1'26: +62.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.3% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.88× Q1'26: 0.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 27 Rev. Ana. 24 EPS Ana. |
Dec 2027 28 Rev. Ana. 23 EPS Ana. |
Dec 2028 23 Rev. Ana. 20 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
Dec 2030 11 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
107.93B
est: 107.76B (+0.2%)
|
111.78B
est: 111.78B (+0.0%)
|
111.70B
est: 112.20B (-0.5%)
|
111.83B
est: 111.63B (+0.2%)
|
122.02B
est: 121.21B (+0.7%)
|
126.95B
est: 126.74B (+0.2%)
|
140.80B
est: 140.15B (+0.5%)
|
176.95B
est: 176.10B (+0.5%)
|
232.26B
est: 258.00B (-10.0%)
|
290.40B
est: 285.38B (+1.8%)
|
309.06B
est: 307.32B (+0.6%)
|
288.77B
268.27B – 315.69B
-6.0% YoY
|
296.19B
268.91B – 335.08B
+2.6% YoY
|
317.06B
316.89B – 317.23B
+7.0% YoY
|
346.10B
317.83B – 385.03B
+9.2% YoY
|
374.72B
344.11B – 416.87B
+8.3% YoY
|
| EBITDA |
46.51B
est: 50.26B (-7.5%)
|
51.06B
est: 52.13B (-2.1%)
|
51.95B
est: 52.33B (-0.7%)
|
51.63B
est: 52.07B (-0.8%)
|
54.43B
est: 56.53B (-3.7%)
|
59.27B
est: 59.11B (+0.3%)
|
65.39B
est: 65.36B (+0.0%)
|
76.80B
est: 82.13B (-6.5%)
|
114.63B
est: 134.01B (-14.5%)
|
137.38B
est: 148.23B (-7.3%)
|
149.44B
est: 159.62B (-6.4%)
|
149.99B
139.34B – 163.97B
-6.0% YoY
|
153.84B
139.67B – 174.04B
+2.6% YoY
|
164.68B
164.59B – 164.77B
+7.0% YoY
|
179.76B
165.08B – 199.98B
+9.2% YoY
|
194.63B
178.73B – 216.52B
+8.3% YoY
|
| EBIT |
43.55B
est: 45.96B (-5.2%)
|
47.86B
est: 47.67B (+0.4%)
|
48.77B
est: 47.85B (+1.9%)
|
47.70B
est: 47.61B (+0.2%)
|
48.77B
est: 51.69B (-5.6%)
|
53.52B
est: 54.05B (-1.0%)
|
59.37B
est: 59.77B (-0.7%)
|
69.44B
est: 75.10B (-7.5%)
|
105.22B
est: 122.24B (-13.9%)
|
128.83B
est: 135.21B (-4.7%)
|
134.75B
est: 145.61B (-7.5%)
|
136.82B
127.11B – 149.57B
-6.0% YoY
|
140.33B
127.41B – 158.76B
+2.6% YoY
|
150.23B
150.15B – 150.31B
+7.0% YoY
|
163.98B
150.59B – 182.43B
+9.2% YoY
|
177.54B
163.04B – 197.52B
+8.3% YoY
|
| Net Income |
34.86B
est: 29.71B (+17.3%)
|
37.93B
est: 33.63B (+12.8%)
|
38.13B
est: 34.69B (+9.9%)
|
38.63B
est: 35.94B (+7.5%)
|
38.95B
est: 36.83B (+5.8%)
|
42.14B
est: 40.00B (+5.4%)
|
47.76B
est: 46.15B (+3.5%)
|
55.53B
est: 54.39B (+2.1%)
|
83.68B
est: 89.90B (-6.9%)
|
100.99B
est: 111.07B (-9.1%)
|
102.43B
est: 106.55B (-3.9%)
|
97.23B
77.88B – 111.24B
-8.7% YoY
|
95.11B
78.70B – 116.56B
-2.2% YoY
|
102.54B
81.09B – 137.37B
+7.8% YoY
|
116.56B
104.19B – 133.61B
+13.7% YoY
|
128.54B
114.89B – 147.34B
+10.3% YoY
|
| SGA |
32.17B
est: 29.44B (+9.3%)
|
32.34B
est: 30.53B (+5.9%)
|
32.12B
est: 30.65B (+4.8%)
|
33.31B
est: 30.49B (+9.2%)
|
35.83B
est: 33.11B (+8.2%)
|
36.89B
est: 34.62B (+6.5%)
|
41.06B
est: 38.28B (+7.2%)
|
50.68B
est: 48.10B (+5.4%)
|
61.60B
est: 67.22B (-8.4%)
|
67.38B
est: 74.35B (-9.4%)
|
70.28B
est: 80.07B (-12.2%)
|
75.23B
69.89B – 82.25B
-6.0% YoY
|
77.17B
70.06B – 87.30B
+2.6% YoY
|
82.60B
82.56B – 82.65B
+7.0% YoY
|
90.17B
82.80B – 100.31B
+9.2% YoY
|
97.62B
89.65B – 108.61B
+8.3% YoY
|
| EPS |
6.78
est: 6.66 (+1.8%)
|
7.50
est: 7.54 (-0.5%)
|
7.71
est: 7.77 (-0.8%)
|
7.98
est: 8.05 (-0.9%)
|
8.21
est: 8.25 (-0.5%)
|
9.03
est: 8.96 (+0.8%)
|
10.40
est: 10.34 (+0.6%)
|
12.26
est: 12.19 (+0.6%)
|
18.67
est: 20.14 (-7.3%)
|
22.67
est: 22.53 (+0.6%)
|
23.06
est: 23.49 (-1.8%)
|
21.14
17.51 – 25.01
-10.0% YoY
|
21.06
17.70 – 26.21
-0.4% YoY
|
23.08
18.23 – 30.89
+9.6% YoY
|
26.21
23.42 – 30.04
+13.6% YoY
|
28.90
25.83 – 33.13
+10.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | 17M | male |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 12M | — |
| Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board | — | female |
| Jamey Millar | Executive Vice President of US Operations & Member of Management Board | — | male |
| John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | — | male |
| Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board | — | male |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | — | female |
| Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | — | female |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | — | female |
| Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NOVO-B.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
